Acquired Company

enGene completed its business combination with FEAC (Forbion European Acquisition Corp) on December 15, 2023, after which ENGN began trading on Nasdaq under the ENGN symbol.

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. enGene Holdings Inc. is based in Montreal, Canada. Show more

Location: 4868 Rue Levy, Montreal, QC, H4R 2P1, Canada | Website: https://www.engene.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

590.1M

52 Wk Range

$2.65 - $11.14

Previous Close

$8.50

Open

$8.54

Volume

446,058

Day Range

$8.39 - $9.20

Enterprise Value

428.2M

Cash

193.7M

Avg Qtr Burn

-24.81M

Insider Ownership

0.09%

Institutional Own.

77.93%

Qtr Updated

10/31/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Detalimogene (EG-70) Details Non-Muscle Invasive Bladder Cancer (NMIBC)	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.